ResearcherWenzhou Medical UniversityActive in the last 2 years
Ruijie Chen
Matched on ORCID iD 0000-0001-5453-5949; OpenAlex author ID A5064149402. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 0, last author 2)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 8
2020: 2 papers · 2021: 2 papers · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 1 paper
Papers 5
- Dual targeting of SLC6A14 and autophagy/macropinocytosis enhances therapeutic efficacy in pancreatic ductal adenocarcinoma. Co-author DOI 10.1042/bcj20250155↗
- ATB0,+-targeted delivery of triptolide prodrugs for safer and more effective pancreatic cancer therapy. Co-author DOI 10.1016/j.bmcl.2020.127728↗
- Dual Targeting EGFR and STAT3 With Erlotinib and Alantolactone Co-Loaded PLGA Nanoparticles for Pancreatic Cancer Treatment. Last author DOI 10.3389/fphar.2021.625084↗
- Synergism between SLC6A14 blockade and gemcitabine in pancreactic cancer: a 1H-NMR-based metabolomic study in pancreatic cancer cells. Co-author DOI 10.1042/bcj20200275↗
- Endocytosis of ATB0,+(SLC6A14)-targeted liposomes for drug delivery and its therapeutic application for pancreatic cancer. Last author DOI 10.1080/17425247.2020.1723544↗
Closest collaborators
The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Longfa Kou · 5 shared papers, 2020–2026 · strength 0.76
- Paper Dual targeting of SLC6A14 and autophagy/macropinocytosis enhances therapeutic efficacy in pancreatic ductal adenocarcin… DOI 10.1042/bcj20250155↗
- Paper Dual Targeting EGFR and STAT3 With Erlotinib and Alantolactone Co-Loaded PLGA Nanoparticles for Pancreatic Cancer Treat… DOI 10.3389/fphar.2021.625084↗
- Paper ATB0,+-targeted delivery of triptolide prodrugs for safer and more effective pancreatic cancer therapy. DOI 10.1016/j.bmcl.2020.127728↗
- Vadivel Ganapathy · 3 shared papers, 2020–2026 · strength 0.51
- Paper Dual targeting of SLC6A14 and autophagy/macropinocytosis enhances therapeutic efficacy in pancreatic ductal adenocarcin… DOI 10.1042/bcj20250155↗
- Paper Synergism between SLC6A14 blockade and gemcitabine in pancreactic cancer: a 1H-NMR-based metabolomic study in pancreati… DOI 10.1042/bcj20200275↗
- Paper Endocytosis of ATB0,+(SLC6A14)-targeted liposomes for drug delivery and its therapeutic application for pancreatic canc… DOI 10.1080/17425247.2020.1723544↗
- Yangzom Doma Bhutia · 2 shared papers, 2020–2026 · strength 0.40
- Paper Dual targeting of SLC6A14 and autophagy/macropinocytosis enhances therapeutic efficacy in pancreatic ductal adenocarcin… DOI 10.1042/bcj20250155↗
- Paper Synergism between SLC6A14 blockade and gemcitabine in pancreactic cancer: a 1H-NMR-based metabolomic study in pancreati… DOI 10.1042/bcj20200275↗
- Mosharaf Mahmud Syed · 1 shared paper, 2026 · strength 0.29
- Shihui Bao · 2 shared papers, 2021 · strength 0.25
- Hailun Zheng · 2 shared papers, 2020–2021 · strength 0.24
- Paper Dual Targeting EGFR and STAT3 With Erlotinib and Alantolactone Co-Loaded PLGA Nanoparticles for Pancreatic Cancer Treat… DOI 10.3389/fphar.2021.625084↗
- Paper Synergism between SLC6A14 blockade and gemcitabine in pancreactic cancer: a 1H-NMR-based metabolomic study in pancreati… DOI 10.1042/bcj20200275↗
- Dan Wen Lou · 1 shared paper, 2021 · strength 0.12
- Aimin Cai · 1 shared paper, 2020 · strength 0.11
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.